Gadolinium-Based MRI Agents Patents: Who Leads, Where Gaps Are 2026
- 16.3% concentration at the top. The five leading assignees hold 813 of 4,995 records in scope — a real lead, but nowhere near a lock on the field.
- Filing has plateaued, not collapsed. From 2021 to 2024, the last complete filing years, volume moved from 122 to 113 records — a 7% pullback, not a retreat.
- Medicinal preparations dominate the claim map. 83.4% of records sit in A61K, but organo-metallic chemistry (C07F, 12.8%) and magnetic measurement (G01R, 9.9%) mark where the chemistry and hardware claims diverge.
Filing growth compares 2021 (122 records) with 2024 (113) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,995 records in scope (CR5), not by the ranked leaders only.
What the gadolinium MRI patent record actually shows
Gadolinium-based contrast agents sit at the intersection of coordination chemistry and diagnostic imaging: the chelate has to hold the metal tightly enough to avoid tissue deposition, while still delivering the relaxivity that makes the scan readable. That tension between chelate stability and imaging performance is the throughline across the 4,995 records in scope, filed between 2015 and the 2026 data cut-off.
The dataset spans macrocyclic and linear chelate chemistry, dose-reduction formulations, and the diagnostic hardware and measurement methods used to read the resulting scans. Regulatory pressure around gadolinium retention has pushed some filing activity toward stability and dose claims rather than pure relaxivity gains, a shift visible in how the IPC classes overlap rather than in any single number.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 4,995-record corpus: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Filings rose from 147 in 2017 to a peak of 189 in 2019, then eased. The 2021-to-2024 span — the last stretch that publication lag has fully caught up with — moved from 122 to 113 records, a 7% decline. Years after 2024 in the chart are undercounted because publication trails filing by roughly 18 months; treat 2025 and 2026 figures as provisional, not as evidence of a steeper drop.
Technology composition by IPC subclass
A61K (medicinal preparations) touches 83.4% of the 4,995 records, confirming that most filings are framed as pharmaceutical compositions rather than pure imaging methods. C07D and C07F, together covering heterocyclic and organo-metallic chemistry, mark the chelate-design claims specifically; G01R and G01N, each under 10%, show that measurement and testing methods are a comparatively thin layer of the total claim space. Records can carry multiple classes, so these shares do not sum to 100%.
Shares are the percentage of the 4,995 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Gadolinium-Based MRI Agents with Eureka
This page is one run against one query. Ask Eureka your own question about gadolinium-based mri agents and every answer comes back with the patent numbers behind it.
Try EurekaA representative claim on relaxivity improvement
MRI contrast agent having gadolinium complex (US8901294B2)
The filing centres on a DO3A-tranexamic acid or ester compound used to form a gadolinium complex, claimed to deliver higher relaxivity than commercially available contrast agents at the time, with added bifunctionality suited to liver-targeted imaging.Filed by Kyungpook National University Industry-Academic Cooperation Foundation, published 2014-12-02.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6120751A | Charged lipids and uses for the same | 1,282 |
| 2 | US6028066A | Prodrugs comprising fluorinated amphiphiles | 429 |
| 3 | US6416740B1 | Acoustically active drug delivery systems | 411 |
| 4 | US6139819A | Targeted contrast agents for diagnostic and therapeutic use | 337 |
| 5 | US5846517A | Methods for diagnostic imaging using a renal contrast agent and a vasodilator | 310 |
| 6 | US5480990A | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents | 303 |
| 7 | US6123923A | Optoacoustic contrast agents and methods for their use | 295 |
| 8 | US6521211B1 | Methods of imaging and treatment with targeted compositions | 290 |
| 9 | US6231834B1 | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of sa… | 278 |
| 10 | US5385893A | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents | 277 |
Citation counts favour older, foundational filings within this searched corpus — they signal influence on later drafting, not present-day commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing data implies for strategy
Three read-throughs from the trend, concentration and citation data — useful for deciding where a new filing has room, and where it lands on top of dense prior art.
A real lead, not a lock
The top five assignees hold 813 records (16.3% of the field) and the top ten hold 1,267 (25.4%). That leaves roughly three-quarters of the corpus spread across a long tail of academic centres, single-product filers and cross-licensed research groups.
A plateau, read carefully
The -7% shift from 2021 to 2024 is measured, not a cliff, and it is the last window where publication lag has mostly caught up. Reading 2025-2026 dips as a further decline would be premature given the roughly 18-month lag between filing and publication.
Pharmaceutical framing dominates
Most filings are drafted as medicinal preparations rather than pure diagnostic methods, which routes examination through pharmaceutical composition art even when the underlying advance is chelate chemistry or imaging hardware.
Influence sits with older art
The most heavily cited records in this corpus date to earlier filing cycles and cover foundational delivery and targeting concepts rather than the latest chelate variants — a reminder that citation counts reward age, not current commercial weight.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to gadolinium-based mri agents, with the prior art for and against each one.
Who is filing, and where the field is still open
The ranked assignee list covers 100 companies across the 4,995-record corpus. Momentum among the leading filers has cooled sharply in the most recent year, which is where the white space for new entrants opens up.
A clear but not dominant leader
The top-ranked assignee holds 346 records against a fifth-place figure of 105 and a tenth-place figure of 83 — a steep drop-off after the leader, then a much flatter curve across the rest of the ranked group.
Leading filers have gone quiet
Several of the assignees with the deepest filing histories in this corpus, including university systems and established imaging companies, show zero filings in the latest tracked year — a -100% year-over-year move for at least one.
Co-filing is concentrated, not common
Only ten co-assignee pairs appear in the corpus, with the strongest pairing appearing 57 times — evidence that most gadolinium MRI IP is filed by single entities rather than through joint ventures or shared research consortia.
| Assignee | Recent year | YoY |
|---|---|---|
| Bracco Imaging S.p.A. | 0 | -100% |
| Board of Regents, The University of Texas System | 0 | — |
| The Regents of the University of California | 0 | — |
| Dyax Corp. | 0 | — |
| Guerbet SA | 0 | — |
| The Dow Chemical Company | 0 | — |
| ImaRx Pharmaceutical Corp. | 0 | — |
| EPIX Pharmaceuticals Inc. | 0 | — |
Where to take this analysis
The trend and ranking data point to specific next checks rather than a single conclusion.
Check freedom to operate on chelate stability claims
Given how thin C07F and G01N coverage is relative to A61K, a stability or testing-method claim may have more room than a straight relaxivity claim.
Explore claim scope in EurekaWatch the quiet leaders for licensing signals
Zero filings in the latest year from several long-standing assignees is worth tracking against litigation and licensing activity, not just filing counts.
Track assignee activity in EurekaRevisit the trend once 2025-2026 fully publishes
Publication lag means the most recent two years understate real filing activity; re-run this view after another publication cycle before concluding the field is shrinking.
Set an alert in EurekaCommon questions on gadolinium MRI agent patents
The leading assignee in this corpus holds 346 of the 4,995 records in scope, well ahead of the fifth-ranked assignee at 105. Together the top five assignees account for 813 records, or 16.3% of the field, and the top ten account for 25.4%. That leaves roughly three-quarters of the corpus spread across a long tail of universities, smaller imaging firms and single-filing entrants, so no one company controls the space outright.
Filing moved from 122 records in 2021 to 113 in 2024, a 7% decline over that span, which is the most recent window where publication has largely caught up with filing activity. Numbers for 2025 and 2026 look lower still, but that reflects the roughly 18-month lag between filing and publication rather than a genuine drop. A plateau is a more accurate description than a slowdown based on the data available now.
US8901294B2 claims a gadolinium complex built from a DO3A-tranexamic acid or ester compound, positioned as delivering higher relaxivity than the contrast agents commercially available when it was filed. It also claims bifunctionality suited to liver-targeted imaging, which narrows its practical scope to that specific chelate structure and its stated imaging application rather than gadolinium chelates generally. Anyone designing a competing liver-targeted agent should check this claim's specific chemical scope before assuming it blocks a different chelate backbone.
The IPC composition shows heavy density in A61K medicinal preparations (83.4% of records) but comparatively thin coverage in magnetic measurement methods (G01R, 9.9%) and material testing (G01N, 7.8%). Bifunctional, liver-targeted chelate designs and dose-reduction formulation claims also sit in a smaller slice of the corpus relative to core relaxivity claims. These thinner classes are worth a dedicated freedom-to-operate check rather than an assumption of open space, since thin coverage in an IPC class does not guarantee no blocking claims exist.
With the top five assignees holding 16.3% of the 4,995 records and the top ten holding 25.4%, this field shows moderate concentration: a genuine leader exists, but the drop from first to fifth place is far steeper than the gap from fifth to tenth. That shape points to one or two companies with an early, durable filing advantage, followed by a broad, comparatively even field of smaller filers rather than a tight oligopoly.
Research Gadolinium-Based MRI Agents in depth with Eureka
Go past this page: query the whole gadolinium-based mri agents corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.